Ely Lilly Offers $35 Insulin Co-Pay in Response to COVID-19

Eli Lilly yesterday introduced a $35 monthly insulin co-pay for patients with or without commercial insurance to ensure they have access to the diabetes drug during the COVID-19 crisis.

The new co-pay card program covers most Lilly insulins, including all Humalog formulations, and all existing cards have been reset to a $35 co-pay.

The cards are not available for patients with government insurance, such as Medicaid and Medicare, or those getting state assistance.

In January, Lilly announced that, by mid-April, it would offer half-priced versions of its Humalog Mix75/25 KwikPen (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog Junior KwikPen (insulin lispro injection 100 units/mL). It said the products will be sold in five-packs at a list price of $265.20 (DID, Jan. 22).